Imetelstat
- Generic Name
- Imetelstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C148H211N68O53P13S13
- CAS Number
- 868169-64-6
- Unique Ingredient Identifier
- F60NE4XB53
- Background
Imetelstat is under investigation in clinical trial NCT01916187 (Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT06247787
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Expanded Access for Treatment With Imetelstat
- Conditions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Geron Corporation
- Registration Number
- NCT05937568
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT05371964
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Texas Oncology, Tyler, Texas, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 320
- Registration Number
- NCT04576156
- Locations
- 🇺🇸
Memorial Care, Long Beach, California, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California, United States
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 289
- Registration Number
- NCT02598661
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States
🇧🇪UZ Leuven - Campus Gasthuisberg, Leuven, Belgium
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- NCIC Clinical Trials Group
- Registration Number
- NCT01916187
- Locations
- 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT01731951
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
- Conditions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01568632
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01243073
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸MDACC - Orlando, Orlando, Florida, United States
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT01137968
- Locations
- 🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.